Company logo
Sector: Healthcare
Industry: Biotechnology

Amicus Therapeutics Inc

Ticker - FOLD
Country: US
Exchange: NASDAQ

Monitor Performance using this Dynamic, Always Current, Periodic Table of Investments

Data:

Time:

Alignment:

About Amicus Therapeutics Inc

  • Company Overview     Fold Therapeutics, Inc. (FOLD) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapeutics for severe genetic diseases, particularly those related to protein misfolding and degradation. The company employs a proprietary platform to develop drugs aimed at treating unmet medical needs in rare conditions.
  • Business Model     FOLD operates under a biotechnology business model, focusing on the research and development (R&D) of innovative therapies. The company aims to leverage its platform to create therapeutics, which may reduce development costs and timeframes. Collaboration with academic institutions and industry partners is essential to enhance its pipeline and share risks associated with drug development.
  • Core Products and Pipeline     FOLD's primary product candidates target diseases resulting from misfolded proteins, including its lead drug candidate, “AT-GAA” (also referred to as PRX-102), developed for the treatment of Fabry disease, a rare lysosomal storage disorder. Other notable candidates in its pipeline focus on conditions such as late-onset Pompe disease and additional lysosomal disorders. The company's proprietary approach includes leveraging small molecules and biologics to address these conditions.
  • Financial Performance     While FOLD is in the clinical-stage phase with several products in development, the company has not yet generated significant revenue from product sales. Funding primarily comes from equity financing and grants. Investors should closely monitor R&D expenditures, clinical trial outcomes, and upcoming regulatory submissions, as these factors will heavily influence the company's cash flow and overall financial stability.
  • Competitive Position     FOLD operates in a highly competitive biotechnology landscape that includes established pharmaceutical companies and emerging biotech firms focusing on the same rare diseases. Its unique selling proposition lies in its proprietary drug development platform and the specificity of its product candidates. Remaining adaptive to competitive advancements and maintaining innovative pipelines is critical for sustaining long-term growth.
  • Market Context     The demand for therapies addressing rare genetic disorders is growing, driven by advancements in genetic research and increased awareness. Regulatory incentives for orphan drugs provide a favorable environment for FOLD, allowing for potential market exclusivity and financial benefits. Investors should consider overall trends in precision medicine and shifts in healthcare policy that may affect market dynamics and investment potential.
  • Risks and Challenges     FOLD faces substantial risks typical in biotechnology, including clinical trial failures, regulatory hurdles, and competition from alternative therapies. Analysis of their candidates' clinical trial progress should be a priority for investors. Additionally, the need for continued funding for R&D poses a financial risk, which could impact the company's valuation if there are delays in achieving developmental milestones or obtaining regulatory approvals.
    • SWOT ANALYSIS

    SWOT Analysis is a strategic planning tool used to identify and understand the key factors that can impact a business or project. What are the key factors for gaining a competitive market share advantage? Also, what potential threats should we be wary of during our Process?

    STRENGTHS

    • Strong pipeline focused on rare and genetic diseases, which tend to have less competition.
    • Established brand reputation and industry relationships that facilitate partnerships.
    • Innovative product offerings with proven clinical results that enhance market positioning.

    WEAKNESSES

    • High dependency on a limited number of products for revenue generation, leading to risk concentration.
    • Substantial R&D expenses that may pressure profitability and cash flows.

    OPPORTUNITIES

    • Diversification through potential new product development and expansion into new therapeutic areas.
    • Strategic partnerships with larger pharmaceutical companies to enhance distribution and market reach.

    THREATS

    • Intense competition from both established companies and emerging biotech firms that could affect market share.
    • Regulatory risks associated with drug approval processes that may delay product launches.

    Please enjoy this free portfolio visualization and monitoring tool. Click Install from the address bar for easy and fast future access.

    Paid accounts can visualize any portfolio or watchlist in this performance visualization… plus a million other cool things — including daily data, sharing custom tables for the assets you care about, industry-leading portfolio backtesting, and full portfolio strategy analytics. Both individual and professional versions are supported.

    Performance Disclosure

    This portfolio is hypothetical.


    This is a historical simulation of the portfolio performance an investor would have obtained had you invested in the same selections at the beginning of the simulation. This report provides information on how the portfolio holdings would have changed and would have performed for a certain period. We have strived to reduce or eliminate potential biases in the process to provide the most accurate assessment of the performance prospects of the strategy. However, it may not be possible for any historical simulation to completely ensure it is free of all biases.


    Please see
    Gold Standard for Portfolio Backtesting and
    Seven Deadly Sins of Portfolio Backtesting
    for a more complete understanding of risks and biases when backtesting portfolio strategies.


    Backtested strategies also run the risk of cherry picking. Cherry Picking is when the author of the backtest has created many variations and is presenting one of the variations that is more favorable. This research was not produced in whole or in part by cherry picking.


    This simulation is based on an account with tax exempt or tax deferred growth. Taxable accounts will have to pay the appropriate taxes for dividends, interest, and capital gains, which will decrease the performance depicted.


    This simulation is not based on actual trading accounts or account composites which may or may not exist for this strategy and may be materially different including worse than the performance illustrated above. Past performance is not necessarily indicative of future performance. Performance results including risk and diversification measures are not guaranteed to persist in the future.


    This historical performance simulation has been adjusted to reflect estimated management fees.


    The suitability of this portfolio strategy requires that you have thoughtfully and accurately completed your investor objectives from your accounts’ Investment Policy Statement. Login


    Diversification strategies alone cannot assure a successful investment outcome. Strategies offering greater diversification also fail to guarantee any reduction in loss of capital.


    Your ability to follow this investment strategy is a risk. Investors often dispose of successful strategies at inopportune times thus turning potentially profitable strategies into losses.


    Portfolio data is taken from sources believed to be accurate, however, there is no warranty or guarantee as to the accuracy or completeness of data and statistical calculations thereupon. Portfolio ThinkTank does not furnish investment advice without an investment advisory agreement.


    The period of time selected for analysis may have a significant bearing on the relative attractiveness of the strategy and the strategy versus another portfolio or benchmark. The author of the strategy controls the default period of time used to analyze performance and from there, users may select any desired period of time from the menu. In general, longer periods, greater diversification and lower concentrations of holdings result in more credible, more persistent performance evaluations.


    If this strategy includes predictions created by our deep learning neural net, there are additional risks that portfolio strategies and their backtested performance may have risks of having the data be overfit and consequently perform better in the backtest than it may in real account performance. We manage these risks regularly and in many ways. However, due to the attention mechanisms in a deep learning neural network, it may not be possible to eliminate these risks. To learn if your portfolio strategy is built using predictions from a neural network or to better understand our mitigation policies, we invite you to start a conversation: hello@gravityinvestments.com